(VIANEWS) – GRAM CAR CARRIERS (GCC.OL), SPAREBANKEN ØST (SPOG.OL), BOUVET (BOUV.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. GRAM CAR CARRIERS (GCC.OL)
16.3% sales growth and 35.2% return on equity
Gram Car Carriers ASA, through its subsidiaries, operates as a tonnage supplier worldwide. The company invests in and operates assets in the pure car and truck carrier shipping segment. It also offers commercial management services for the 19 owned carriers and 1 vessel managed by third party. The company was founded in 2006 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, GRAM CAR CARRIERS has a trailing twelve months EPS of kr23.28.
PE Ratio
GRAM CAR CARRIERS has a trailing twelve months price to earnings ratio of 8.72. Meaning, the purchaser of the share is investing kr8.72 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.2%.
Volume
Today’s last reported volume for GRAM CAR CARRIERS is 9102 which is 78.15% below its average volume of 41662.
More news about GRAM CAR CARRIERS.
2. SPAREBANKEN ØST (SPOG.OL)
15.3% sales growth and 9.08% return on equity
Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; current accounts; home mortgage loans; and mortgage loans for new and used cars. It also provides vehicles, houses and contents, boats, and leisure insurance products, as well as life and health insurance products; and shares and funds trading services. In addition, the company buys, sells, and stores cryptocurrencies, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr7.09.
PE Ratio
SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 7.38. Meaning, the purchaser of the share is investing kr7.38 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
More news about SPAREBANKEN ØST.
3. BOUVET (BOUV.OL)
9.7% sales growth and 60.9% return on equity
Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. Bouvet ASA was founded in 1995 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, BOUVET has a trailing twelve months EPS of kr3.15.
PE Ratio
BOUVET has a trailing twelve months price to earnings ratio of 19.33. Meaning, the purchaser of the share is investing kr19.33 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 3.22B for the twelve trailing months.
More news about BOUVET.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 15.31% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.5. Meaning, the purchaser of the share is investing kr23.5 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.31%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 438.33M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 30.28.
More news about VISTIN PHARMA.
